Glaxosmithkline | GSK - Trade Debtors


Glaxosmithkline reported GBP10.45B in Trade Debtors for its fiscal quarter ending in December of 2025.





Trade Debtors Change Date
AbbVie USD 12.59B 180M Dec/2025
Amgen USD 9.14B 432M Mar/2026
AstraZeneca USD 17.88B 1.17B Mar/2026
Aurora Cannabis CAD 48.26M 1.53M Dec/2025
Bausch Health Companies USD 2.19B 160M Mar/2026
Bristol-Myers Squibb USD 14.36B 164M Mar/2026
Canopy Growth CAD 140.42M 113.56M Dec/2025
Corcept Therapeutics USD 39.07M 20.71M Mar/2026
Drreddys Laboratories INR 1.41B 11.6M Dec/2025
Eli Lilly USD 21.18B 1.02B Mar/2026
GlaxoSmithKline GBP 7.94B 178M Mar/2026
Glaxosmithkline GBP 10.45B 707.81M Dec/2025
J&J USD 21.33B 3.72B Dec/2025
Merck USD 11.78B 345M Dec/2025
Novartis USD 9.6B 2.69B Mar/2026
Pacira USD 125.64M 1.57M Mar/2026
Perrigo USD 697.1M 84.3M Mar/2026
Pfizer USD 16.17B 332M Mar/2026
Phibro Animal Health USD 215.87M 2.02M Dec/2025
Prestige Brands USD 191.92M 1.46M Mar/2026
Roche Holding CHF 11.9B 460M Dec/2025
Sanofi EUR 482M 85M Mar/2026
Supernus Pharmaceuticals USD 182.18M 5.62M Mar/2026
Takeda JPY 876.35B 118.43B Mar/2026
Teva Pharmaceutical Industries USD 3.39B 316M Mar/2026
Zoetis USD 1.51B 84M Mar/2026